期刊文献+

血脉通颗粒治疗颈动脉粥样硬化的临床研究 被引量:12

Clinical Study on Effect of Xuemaitong Granule on Cervical Artherosclerosis
下载PDF
导出
摘要 目的观察血脉通颗粒对颈动脉粥样硬化的作用机理。方法采用彩色多谱勒超声技术从高血压或高血脂患者中检测出77例颈动脉硬化的病人,随机分成治疗组和对照组,治疗组采用血脉通颗粒10 g,每日3次,口服;对照组采用舒降之20 mg,每晚顿服、疗程均为6个月。观察治疗前后增厚的颈动脉内膜中层与斑块消退的情况、血脂变化、MDA、SOD、MMP-1及上述药物的不良反应。结果2组病人颈动脉内膜中层增厚未进一步发展,斑块有所消退,但治疗前后无显著性差异,治疗组治疗前后TG、LPa、ox-LDL、MDA、基质金属蛋白酶MMP-1均有明显降低,HDL-C、SOD升高明显,统计学有显著性差异。2组无明显不良反应。结论血脉通颗粒可有效调控血脂,改善血管内皮功能、稳定斑块。 OBJECTIVE To observe the mechanism of Xuemaitong Granule on cervical artherosclerosis. METHOD Doppler ultrasound technique was adopted to choose 77 cervical artherosclerosis patients from those with hypertension or hyperlipemia, which were divided randomly into a treatment group and a control group, treated with Xuemaitong Granule (10 grams at a time, three times daily) and Simvastatin(20 mg/qn) respectively for 6 months. RESULT In both groups, the thickening of the middle layer of cervical endarterium did not develop further and the plaques were resolved, but with no marked difference as compared with the conditions before the treatment. In the treatment group, TG, LPa, ox- LDL, SOD, MDA and MMP- 1 dropped greatly and HDL- C increased greatly, with marked statistical significance. No undesirable reactions were found in both groups. CONCLUSION Xuemaitong Graunle can effectively control blood lipid, improve the function of blood vessel endodermis and prevent the development of the plaques.
出处 《南京中医药大学学报》 CAS CSCD 2006年第3期162-164,共3页 Journal of Nanjing University of Traditional Chinese Medicine
基金 江苏省中医管理局资助项目(9970)
关键词 颈动脉粥样硬化 血脉通颗粒 基质金属蛋白酶 cervical artherosclerosis Xuemaitong Granule MMP - 1
  • 相关文献

参考文献3

二级参考文献17

  • 1李健斋,陈曼丽,马正中,贺承松,褚德发.尸检冠状动脉粥样硬化与生前血脂水平的相关分析[J].中华心血管病杂志,1996,24(4):278-281. 被引量:36
  • 2[1]Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem, 1983, 52: 224~261.
  • 3[2]McMurrag HF,Parthasarathy S,Steinberg D.Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest, 1993,92:1004 ~ 1008.
  • 4[3]Reid VC,Mitchinson MJ,Skepper JN. Cytotoxicity of oxidized low-density lipoprotein to mouse peritoneal macrophages: an ultrastructural study. J Pathol. 1993,171: 321~328.
  • 5[4]Hein TW,Kuo L. LDLs impair vasomotor function of the coronary microcirculation. Circ Res, 1998,83:404~414.
  • 6[5]Lehtimaki T. Lehtinen S. Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.Arterioscler Thromb Vasc Biol, 1999,19:23~27.
  • 7[6]Oshima R,Ikeda T,Watanabe K,et al. Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis, 1998,137:13~22.
  • 8[1]Nagase H.Activation mechanis ms of matrix metalloproteinases.Biol Che m,1997,378:151-160.
  • 9[2]Brew K,Dinakarpandian D,Nagase H.Tissu e inhibitors of metalloproteinases:evolu tion,structure and function.Biochim Biop hys Acta,2000,1477:267-283.
  • 10[3]Rajavashisth TB,Xu XP,Jovinge S.Membra ne type 1 matrix metalloproteinase expre ssion in human atherosclerotic plaques:e vidence for activation by proinflammator y mediators.Circulation,1999,99:3103-310 9.

共引文献64

同被引文献178

引证文献12

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部